NEWS & MEDIA
September 18, 2019
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response
January 1, 2019
Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis
January 1, 2019
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the efects of anticancer therapeutics in bladder cancer
November 11, 2017
GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents
PARTNERING
As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations.